These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 30060179)
1. Hepatic Steatosis Is Associated With Adverse Molecular Signatures in Subjects Without Diabetes. Pietzner M; Budde K; Homuth G; Kastenmüller G; Henning AK; Artati A; Krumsiek J; Völzke H; Adamski J; Lerch MM; Kühn JP; Nauck M; Friedrich N J Clin Endocrinol Metab; 2018 Oct; 103(10):3856-3868. PubMed ID: 30060179 [TBL] [Abstract][Full Text] [Related]
2. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis. Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312 [TBL] [Abstract][Full Text] [Related]
3. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology. Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000 [TBL] [Abstract][Full Text] [Related]
4. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes. Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690 [TBL] [Abstract][Full Text] [Related]
5. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Cuthbertson DJ; Weickert MO; Lythgoe D; Sprung VS; Dobson R; Shoajee-Moradie F; Umpleby M; Pfeiffer AF; Thomas EL; Bell JD; Jones H; Kemp GJ Eur J Endocrinol; 2014 Nov; 171(5):561-9. PubMed ID: 25298375 [TBL] [Abstract][Full Text] [Related]
6. Amino Acid Metabolism is Altered in Adolescents with Nonalcoholic Fatty Liver Disease-An Untargeted, High Resolution Metabolomics Study. Jin R; Banton S; Tran VT; Konomi JV; Li S; Jones DP; Vos MB J Pediatr; 2016 May; 172():14-19.e5. PubMed ID: 26858195 [TBL] [Abstract][Full Text] [Related]
7. Ellagic Acid Alleviates Hepatic Oxidative Stress and Insulin Resistance in Diabetic Female Rats. Polce SA; Burke C; França LM; Kramer B; de Andrade Paes AM; Carrillo-Sepulveda MA Nutrients; 2018 Apr; 10(5):. PubMed ID: 29693586 [TBL] [Abstract][Full Text] [Related]
8. Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. Brouwers B; Schrauwen-Hinderling VB; Jelenik T; Gemmink A; Havekes B; Bruls Y; Dahlmans D; Roden M; Hesselink MKC; Schrauwen P Clin Sci (Lond); 2017 Aug; 131(15):1905-1917. PubMed ID: 28620012 [TBL] [Abstract][Full Text] [Related]
9. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634 [TBL] [Abstract][Full Text] [Related]
10. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers. Bannas P; Kramer H; Hernando D; Agni R; Cunningham AM; Mandal R; Motosugi U; Sharma SD; Munoz del Rio A; Fernandez L; Reeder SB Hepatology; 2015 Nov; 62(5):1444-55. PubMed ID: 26224591 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of sleep deprivation-induced hepatic steatosis and insulin resistance in mice. Shigiyama F; Kumashiro N; Tsuneoka Y; Igarashi H; Yoshikawa F; Kakehi S; Funato H; Hirose T Am J Physiol Endocrinol Metab; 2018 Nov; 315(5):E848-E858. PubMed ID: 29989853 [TBL] [Abstract][Full Text] [Related]
12. Non-Alcoholic Fatty Liver Disease. Engin A Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211 [TBL] [Abstract][Full Text] [Related]
13. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease. Wu T; Ye J; Shao C; Li F; Lin Y; Ma Q; Wang W; Feng S; Zhong B Front Endocrinol (Lausanne); 2021; 12():691556. PubMed ID: 34899591 [TBL] [Abstract][Full Text] [Related]
14. Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. Carlier A; Phan F; Szpigel A; Hajduch E; Salem JE; Gautheron J; Le Goff W; Guérin M; Lachkar F; Ratziu V; Hartemann A; Ferré P; Foufelle F; Bourron O Cell Rep Med; 2020 Dec; 1(9):100154. PubMed ID: 33377125 [TBL] [Abstract][Full Text] [Related]
15. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice. Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216 [TBL] [Abstract][Full Text] [Related]
16. Predicting hepatic steatosis and liver fat content in obese children based on biochemical parameters and anthropometry. Zhang HX; Xu XQ; Fu JF; Lai C; Chen XF Pediatr Obes; 2015 Apr; 10(2):112-7. PubMed ID: 24903159 [TBL] [Abstract][Full Text] [Related]
17. A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD. Ashworth WB; Davies NA; Bogle ID PLoS Comput Biol; 2016 Sep; 12(9):e1005105. PubMed ID: 27632189 [TBL] [Abstract][Full Text] [Related]
18. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice. Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032 [TBL] [Abstract][Full Text] [Related]
19. [ANTHROPOMETRIC CHARACTERISTICS AND PARAMETERS OF LIPID-CARBOHYDRATE METABOLISM IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND HYPERTENSION DEPENDING ON THE DEGREE OF HEPATIC STEATOSIS]. Babak О; Bashkirova А Georgian Med News; 2018 Nov; (284):59-65. PubMed ID: 30618391 [TBL] [Abstract][Full Text] [Related]
20. Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease. Moreno-Vedia J; Rosales R; Ozcariz E; Llop D; Lahuerta M; Benavent M; Rodríguez-Calvo R; Plana N; Pedragosa A; Masana L; Castro A; Ibarretxe D; Girona J Front Endocrinol (Lausanne); 2021; 12():775677. PubMed ID: 35082753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]